Separately, a retrospective analysis suggested that CRP elevation was predictive of poor outcomes when incorporated into the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) model for patients receiving axitinib. The gene discussed is CRP; the disease is hereditary clear cell renal cell carcinoma.